Substance Use Disorder Documentation: SOAP Notes & MAT Progress Notes

Why SUD Notes Matter Clinically and Regulatorily

An SUD note is a clinical document first: it records the person's reported use, your observations, your diagnostic impression, and the treatment plan. It is also a regulatory document. Outpatient MAT for OUD, counseling requirements tied to buprenorphine prescribing, and controlled-substance prescribing all depend on a chart that shows you assessed risk, offered counseling or referral, monitored adherence, and responded to concerning findings.

Person-first language belongs in the record as much as in the room. Prefer 'person with OUD' or 'person with stimulant use disorder' over 'addict' or 'abuser.' Prefer 'return to use' or 'recurrence' over 'relapse' when your setting uses recovery-oriented language — or, if you use 'relapse,' define it clinically (e.g., return to daily heroin use after three months of abstinence). Prefer 'positive UDS for cannabis' over 'dirty urine.' Stigma in the chart can shape how future teams treat the person and how the person experiences care.

What to Document in Every SUD Encounter

Whether the visit is an intake or a brief MAT follow-up, these elements should appear when clinically relevant. Missing them is one of the most common reasons SUD notes fail medical-necessity or program review.

• Substance(s) — primary substance and any co-occurring substances (alcohol, opioids, stimulants, benzodiazepines, cannabis, nicotine, other)
• Amount and frequency — approximate dose or quantity, route, and how often; note changes since last visit
• Last use — date and time of last use for each relevant substance; critical for withdrawal risk and induction timing
• Withdrawal — subjective symptoms and objective signs; score with COWS or CIWA when indicated
• Cravings — intensity (e.g., 0–10), triggers, and coping used
• Psychosocial context — housing, employment, legal involvement, relationships, trauma history when it informs care
• Readiness to change — stage of change, goals the person states in their own words, ambivalence if present

Also document overdose history, naloxone access and teaching, and any high-risk use patterns (injecting alone, mixing opioids with benzodiazepines or alcohol). Link functional impact to medical necessity the way you would in a depression progress note: missed work, strained relationships, medical complications, or impaired parenting capacity when relevant.

MAT Documentation: Buprenorphine and Naltrexone

Medication for addiction treatment (MAT) — including buprenorphine/naloxone for OUD and naltrexone (oral or extended-release injectable) for OUD or AUD — requires documentation that shows dosing, adherence, counseling or behavioral support, and response. Treat MAT notes with the same rigor you use for a psychiatric medication management note.

Buprenorphine / buprenorphine-naloxone

• Formulation, dose, frequency, and route (e.g., buprenorphine-naloxone 8/2 mg SL BID)
• Induction vs maintenance; days since last full-agonist use if inducting
• Adherence (doses taken as prescribed; diversion or misuse concerns addressed factually)
• Side effects (constipation, sedation, precipitated withdrawal if applicable)
• Counseling or behavioral therapy offered, accepted, declined, or referred — and why
• PDMP review when required or clinically appropriate, with date reviewed
• Naloxone prescribed or confirmed on hand; overdose education documented

Naltrexone (oral or XR-injectable)

• Indication (OUD, AUD, or both) and formulation
• For XR-naltrexone: injection date, site, next due date; for oral: daily adherence
• Opioid-free interval before start when treating OUD; naloxone challenge if used
• Hepatic labs when clinically indicated; counseling on opioid blockade and acute pain planning
• Craving reduction and drinking or opioid-use days since last visit

COWS and CIWA When Relevant

Standardized withdrawal scales turn subjective discomfort into auditable numbers and guide dosing decisions. Use them when the person may be in opioid or alcohol withdrawal — and document the score, the items driving it, and how the score changed your plan.

A note that says 'mild withdrawal' without a score is harder to defend than 'COWS 14 — moderate; inducted with buprenorphine-naloxone 4/1 mg SL after confirming last heroin use ~18 hours ago; recheck COWS in 45–60 minutes.'

UDS Interpretation Without Stigma

Urine drug screens are clinical data, not moral tests. Document the panel ordered, the result, immunoassay vs confirmatory testing when relevant, prescribed medications that may explain positives, and your clinical interpretation tied to the treatment plan — not character judgments.

• State results factually: 'UDS immunoassay positive for opioids and buprenorphine; negative for cocaine, amphetamines, benzodiazepines, cannabis.'
• Reconcile with the prescribed regimen: expected buprenorphine positive on MAT; unexpected cocaine positive warrants a nonjudgmental discussion and plan adjustment
• Note limitations: immunoassay false positives/negatives; timing of last use; synthetic opioids that may not appear on standard panels
• Document the conversation and shared plan: increased visit frequency, counseling intensification, dose review — not punitive language
• Avoid 'dirty' / 'clean' and 'noncompliant addict' framing; prefer 'unexpected positive for X; discussed with patient; plan as follows'

Dual Diagnosis Documentation Tips

Co-occurring SUD and psychiatric disorders are common. Document both diagnoses with supporting criteria, clarify which symptoms are attributed to intoxication or withdrawal versus an independent mood or psychotic disorder when you can, and show that the plan addresses both. See also how to write psychiatry notes for MSE and risk structure.

• List SUD and psychiatric diagnoses separately with ICD-10 codes (e.g., OUD, moderate, on maintenance therapy; MDD, recurrent, moderate)
• Note temporal relationships: mood symptoms that persist weeks into abstinence vs symptoms that clear with detox
• Screen and document SI/HI every visit — substance use elevates risk; do not skip because the visit 'was only MAT'
• Avoid collapsing everything into 'substance-induced' without evidence; document differentials (R/O substance-induced depressive disorder vs primary MDD)
• Coordinate care: name the therapist, IOP, primary care, or peer support involved when known

SOAP / MAT Progress Note Template

Use this as a fillable skeleton for outpatient SUD and MAT visits. Trim sections that do not apply; expand withdrawal and UDS blocks when they drive the visit.

Four SOAP Examples

Names and details are illustrative. Adapt the structure to your setting and local documentation requirements.

Example 1 — OUD Buprenorphine Follow-Up

Jordan is a 34-year-old person with OUD returning for a routine MAT follow-up on buprenorphine-naloxone.

Example 2 — AUD Medication Management

Priya is a 48-year-old person with AUD starting naltrexone after a recent increase in drinking.

Example 3 — Stimulant Use Disorder, Psychiatry Visit

Marcus is a 29-year-old person with methamphetamine use disorder seen in outpatient psychiatry for mood and use-related insomnia.

Example 4 — Dual Diagnosis: SUD + MDD

Elena is a 41-year-old person with OUD on buprenorphine and recurrent major depression, illustrating how both tracks appear in one note.

Contingency Planning and Safety

Every SUD note should show that you thought ahead about overdose, return to use, and psychiatric crisis — not only today's dose.

• Overdose: naloxone prescribed or confirmed; who was educated; risk of solitary use and polysubstance combinations
• Return-to-use plan: what the person will do if they use again (call clinic, do not use alone, resume MAT promptly) — framed without shame
• Acute pain / surgery: for people on naltrexone or buprenorphine, document counseling about informing other clinicians
• Psychiatric safety: SI/HI every visit; means restriction when relevant; crisis contacts
• Missed visits / unexpected UDS: what the clinic will do (earlier follow-up, counseling intensification) documented as a clinical response, not a punishment narrative

Common Mistakes in SUD Documentation

Stigmatizing or vague language

'Chronic abuser, noncompliant, dirty UDS' communicates judgment and little clinical detail. Prefer person-first terms, specific substances and amounts, and factual UDS interpretation tied to a plan.

Missing last use, amount, and frequency

Without last use and quantity, withdrawal risk and induction timing cannot be reconstructed. Reviewers and covering clinicians need those numbers.

MAT without counseling or behavioral support documented

Even a brief MI intervention or a declined referral should appear in the note. Silence looks like an incomplete plan.

Skipping risk because 'it was only a refill'

Overdose and suicide risk change quickly in SUD populations. A documented negative ('denies SI/HI; naloxone at home') is protective and clinically useful.

UDS as punishment

Unexpected positives should trigger assessment and care adjustment, not chart language that shames the person. Document the discussion and the clinical next step.

Ignoring dual diagnosis

Treating only the substance or only the mood disorder in the note leaves medical necessity incomplete when both are active. Name both and show the plan addresses both.

Let an AI Scribe Draft Your SUD and MAT Notes

SUD visits move fast: last use, cravings, COWS items, UDS review, MAT dosing, counseling, and safety all need to land in the chart before the next person is roomed. Augustun for psychiatry listens during the encounter and drafts a structured SOAP or medication-management note — including substance history details, MSE, and a clear plan — so you can stay present with the person in front of you. You review, edit, and sign.

Augustun supports SOAP and related behavioral-health formats, can draft patient instructions and follow-up plans, and connects to 400+ EHRs through a browser extension so finished notes land where you already chart. It is built for clinical use with HIPAA compliance, and recordings are never stored.

Conclusion

Strong substance use disorder documentation is precise, person-first, and complete enough for both the next clinician and a regulatory reviewer. Capture substance, amount, frequency, last use, withdrawal, cravings, psychosocial context, and readiness. For MAT, document dose, adherence, counseling, and monitoring. Score COWS or CIWA when withdrawal drives decisions. Interpret UDS as clinical data. Address dual diagnosis and safety every time.

Start from the template above, adapt one of the four examples, and build the habit of nonstigmatizing, medically necessary notes. Whether you write them yourself or let an AI scribe draft them for review, clear SUD documentation is part of the care you deliver — not just paperwork after the visit.